Bolt Biotherapeutics (BOLT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BOLT · Stock Price

USD 4.59-2.57 (-35.89%)

Market Cap: $10.0M

Historical price data

Market Cap: $10.0MFounded: 2015HQ: Redwood City, United States

Sector Ranking#191 in Biologics / Biosimilars #73 in Immunotherapy / Immuno-Oncology

Overview

Bolt Biotherapeutics is developing targeted immunotherapies based on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which aims to harness the innate immune system to fight cancer. Founded in 2015 on foundational research from Stanford University, the company's strategy centers on advancing its lead clinical asset, BDC-4182, and leveraging collaborations to expand its pipeline. As a pre-revenue public company, Bolt faces the critical challenge of generating compelling clinical proof-of-concept data to validate its platform and attract further investment or partnership capital in a competitive oncology landscape.

Oncology

Technology Platform

The Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform links tumor-targeting antibodies to proprietary immune-stimulating payloads that activate pattern recognition receptors (PRRs) on innate immune cells within the tumor microenvironment, aiming to generate a systemic anti-cancer immune response.

Funding History

3

Total raised:$248.3M

IPO$100.8MUndisclosedFeb 5, 2021

Series B$54MSofinnova InvestmentsJul 15, 2019

Series A$93.5MNovo VenturesJan 15, 2018

Opportunities

Validation of its lead ISAC, BDC-4182, in the clinically proven Claudin 18.2 space could unlock significant value and partnership interest.

The platform's potential to convert immunologically 'cold' tumors into 'hot' ones addresses a major unmet need in oncology, applicable across multiple cancer types and combinable with existing therapies.

Risk Factors

The company faces binary clinical risk with its lead asset, BDC-4182, and severe financial risk with a low valuation and limited cash runway.

It must also prove its unproven ISAC platform can compete against established and novel modalities in a fiercely competitive innate immuno-oncology landscape.

Competitive Landscape

Bolt competes directly with advanced Claudin 18.2-targeting therapies (bispecifics, CAR-Ts) and broadly within the crowded fields of innate immune engagers and antibody conjugates. Its differentiation hinges on demonstrating superior efficacy or durability via its unique mechanism of targeted PRR agonist delivery.